ArticleChina CDC weekly2025
Analysis of Service Utilization and Medication Adherence Among Attendees of HIV Nonoccupational Post-Exposure Prophylaxis Clinics - China, 2022-2024.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human Immunodeficiency Virus (HIV) nonoccupational post-exposure prophylaxis (nPEP) clinics are specialized healthcare facilities that provide urgent medical interventions to individuals with potential high-risk HIV exposures. This study analyzed utilization patterns of HIV nPEP services in China and examined factors associated with medication adherence among consultees, providing evidence to inform further implementation and optimization of HIV nPEP interventions. Methods: We analyzed nPEP case data collected from the national nPEP data information system between November 1, 2022, and November 1, 2024, using SPSS 29.0 software. Chi-square tests were applied to analyze characteristics of nPEP consultees, and logistic regression models were used to identify factors influencing medication adherence and follow-up compliance among those who initiated treatment. Results: As of November 1, 2024, 924 nPEP clinics nationwide received 54,108 consultees, with 53,405 (98.70%) initiating medication. Most individuals seeking services were male (88.63%), classified as high-risk (83.11%), and heterosexual with multiple partners (67.66%). The "BIC/FTC/TAF" regimen was selected by 63.07% of recipients. Nearly all users (99.03%) completed medication evaluation within 72 hours post-exposure. Among medication users, 60.34% (30,650) adhered to the full 28-day regimen, and 60.10% (30,509) completed either one-month or three-month follow-ups. Multivariate logistic regression analysis identified gender, exposure risk assessment results, exposure population classification, individual preferences, and medication regimen as significant factors influencing both 28-day medication adherence and follow-up compliance ( Conclusions: nPEP clinic consultees in China are predominantly young male heterosexual individuals with multiple sexual partners, with most selecting the Biktarvy regimen. However, both current 28-day medication adherence and follow-up compliance rates remain suboptimal. High-risk men and those receiving the Biktarvy regimen demonstrate superior medication adherence and follow-up compliance compared to other groups. Further research is needed to develop targeted interventions to improve medication adherence and follow-up rates among nPEP recipients. Enhancing adherence and follow-up should be prioritized in future interventions, supported by continuous monitoring to inform timely intervention strategy adjustments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.